Related Experiment Video

Updated: Sep 16, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Review Deciphering the Anticancer Efficacy of Oroxylin A Targeting Dysregulated Oncogenes

Pratibha Pandey1, Subbulakshmi Ganesan2, Sumit Rajotiya3

  • 1Centre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura- 140401, Punjab, India.

Current Gene Therapy
|July 11, 2025
PubMed

Insights

Oroxylin A (OrA), a flavonoid, shows significant anticancer potential against breast carcinoma by inhibiting tumor growth through multiple mechanisms. This review supports OrA as a promising therapeutic agent for breast cancer treatment.

Area of Science:

  • Natural Products Chemistry
  • Oncology
  • Pharmacology

Background:

  • Flavonoids possess demonstrated anti-tumor properties against various human cancers.
  • Oroxylin A (OrA), a monoflavonoid, exhibits potent anticancer effects with minimal toxicity to normal tissues.
  • A systematic review is needed to elucidate OrA's specific mechanisms against breast carcinoma.

Purpose of the Study:

  • To systematically review and report the mechanisms by which Oroxylin A impedes breast carcinoma progression.
  • To analyze the anti-breast cancer potential, structure, and bioavailability of Oroxylin A.
  • To support the development of novel therapeutic strategies for breast cancer.

Main Methods:

  • Comprehensive literature search for studies on Oroxylin A's anticancer properties.
  • Analysis of research detailing OrA's mechanisms of action in various human carcinomas.
  • Inclusion of studies on OrA's structure, bioavailability, and efficacy in breast cancer models.

Main Results:

  • Oroxylin A inhibits breast tumor advancement through multiple pathways, including autophagy, cell cycle arrest, angiogenesis suppression, apoptosis induction, and glycolysis inhibition.
  • OrA demonstrates significant anticancerous potential and specific modes of action across several human carcinomas.
  • Evidence supports OrA's structure, bioavailability, and anti-breast cancer activity.

Conclusions:

  • Oroxylin A exhibits multifaceted anticancer mechanisms relevant to breast carcinoma.
  • OrA's favorable profile suggests its potential as a therapeutic agent for breast cancer.
  • This review highlights Oroxylin A as a promising candidate for developing improved anti-breast cancer therapies.
Keywords:
Oroxylin Abreast cancerflavonoidoncogenes.signalling pathwaytherapeutics

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K